CJC-1295 without DAC (Drug Affinity Complex) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH) designed to enhance pulsatile growth hormone (GH) secretion [1].
CJC-1295 is a modified 30-amino-acid fragment of native GHRH that incorporates substitutions at positions 2, 8, 15, and 27, to increase stability.
Because GH secretion is tightly rhythm-regulated, particularly during sleep, preserving this pulsatile pattern can support metabolic, muscular, and regenerative functions.
Because GH secretion naturally occurs in rhythmic bursts, especially during deep sleep, CJC-1295 without DAC preserves this pattern rather than producing continuous elevation [2].
Once GH is released, it stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates many of GH’s downstream actions, including [3]:
By amplifying both GH and IGF-1 signaling, CJC-1295 without DAC acts as a dual-phase secretagogue.
Two randomized, double-blind, placebo-controlled dose ascending trials of healthy adults (over 28 and 49 days, respectively), characterized the profile of CJC-1295 [4].
In the first trial, participants received one of four ascending single subcutaneous doses of CJC-1295 or placebo. In the second trial, participants received two or three weekly or biweekly injections.
Results showed that:
No serious adverse events or trial withdrawal were reported across either study.
CJC-1295 without DAC amplifies natural pulsatile GH release, creating a metabolic environment that supports gradual, physiologic recomposition.
Key mechanisms underlying these effects include [5]:
A GHRH gene–ablated (GHRHKO) mice was studied to determine whether CJC-1295 can normalize growth and body composition in the absence of endogenous GHRH [5].
Over 5 weeks, mice were split into the following treatment groups:
Results showed that:
This study highlights the therapeutic potential of CJC-1295 in severe GHRH deficiency and underscores the importance of dosing frequency in achieving full physiologic restoration.
CJC-1295 without DAC may support tissue repair and recovery from musculoskeletal injury through its influence on growth hormone–mediated regenerative pathways [6].
Because GH and IGF-1 play roles in:
enhancing their natural pulsatile release can create a biochemical environment favorable for healing.
Key mechanisms underlying these effects include:
Currently, no robust studies exist that investigate these potential effects.
CJC-1295 without DAC offers a distinct therapeutic profile shaped by its shorter half-life and physiologic mimicry of natural growth hormone secretion.
Mimics Natural GH Physiology
Because CJC-1295 without DAC delivers pulsatile GH stimulation, this can reduce the risk of GH receptor desensitization.
Lower Risk of Side Effects
Pulsatile secretagogues tend to cause fewer adverse effects such as:
The intermittent stimulation gives metabolic pathways time to normalize between pulses.
Better Control Over Timing
Users and clinicians can schedule injections around sleep cycles, fasting windows, or training sessions to optimize GH peaks.
Requires More Frequent Injections
Because the peptide is rapidly cleared, achieving meaningful GH pulses may require one to three injections daily. This can reduce convenience and adherence compared to once-weekly DAC formulations.
Shorter Therapeutic Window
Missed doses or inconsistent scheduling can significantly affect outcomes, as the peptide’s benefits depend on steady, rhythmic stimulation.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). CJC-1295 No DAC is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.